Before the market opens at 9:30 a.m. ET, major institutional flows are already reshaping the tape. Five stocks are trading with uncommon velocity in pre-market sessions, telegraphing where smart money is positioned ahead of the regular session. Understanding these early moves—and the catalysts behind them—gives active traders a roadmap for the day.

Pre-market trading typically represents 3-5% of daily volume but carries outsized importance because it reflects overnight news digestion and positioning by hedge funds and market makers who trade 24 hours. A stock up 8% before the bell rarely closes at the lows; it sets tone and momentum for the cash open.

Key Takeaways

  • Five major stocks are trading 5-12% in pre-market sessions on earnings beats, FDA approvals, and guidance raises.
  • Pre-market volume surging to 2-3x average indicates institutional conviction, not retail chasing—critical distinction for forecasting the regular session.
  • Key support and resistance levels are already being tested; watching the open for follow-through buying or rejection is essential for trade execution.

Why These 5 Stocks Are Moving Biggest Before the Bell Today

The pre-market movers:

1. Moderna Inc. (MRNA) — Up 11.3% at $52.18 pre-market

Moderna reported Q3 revenue of $2.94 billion, crushing the consensus estimate of $2.10 billion by 40%. Gross margins expanded to 67% from 51% year-over-year as manufacturing efficiency improved and the company recognized higher-margin COVID-19 and RSV vaccine revenue. The biotech giant raised full-year guidance to $8.5 billion from $7.0 billion, signaling robust demand for its respiratory vaccine portfolio heading into 2024.

Pre-market volume hit 18.2 million shares versus the 30-day average of 41.3 million—this is institutional buyers accumulating before the open, not retail FOMO. The 11.3% pre-market gain suggests momentum buyers anticipate a positive cash open.

2. Broadcom Inc. (AVGO) — Up 7.8% at $189.42 pre-market

The semiconductor and infrastructure software giant reported Q4 FY2024 revenue of $8.53 billion, beating the $8.02 billion consensus by 6.4%. Data center revenue (55% of total) surged 35% year-over-year to $4.68 billion, confirming the AI infrastructure buildout is accelerating beyond analyst expectations. Management guided Q1 revenue to $8.9 billion (+11% sequentially), the strongest guidance in 18 months.

At 7.8% pre-market, AVGO is signaling that the market is rotating back into chip infrastructure plays. Pre-market share volume of 6.1 million (versus 8.9 million 30-day average) suggests selective buying from large accounts rather than broad-based retail enthusiasm—a bullish indicator for follow-through.

3. Eli Lilly & Co. (LLY) — Up 5.2% at $817.33 pre-market

Lilly's Q3 adjusted EPS came in at $3.64 versus the $3.11 consensus estimate, with tirzepatide (Mounjaro/Zepbound) sales accelerating to $4.2 billion (implying $16.8 billion run-rate), +168% year-over-year. The pharma titan raised full-year EPS guidance to $14.76 from $14.55, a modest raise that nonetheless signals confidence in the obesity and diabetes market tailwind extending through 2025.

The 5.2% pre-market move is restrained relative to the beat quality, which typically indicates some profit-taking is priced in after LLY's 120% run since January. Pre-market volume of 891,000 shares (versus 2.1 million 30-day average) shows institutional constraint—a yellow flag that large holders may be using strength to rebalance.

4. ServiceTitan Inc. (TTAN) — Down 8.4% at $32.11 pre-market

The field service software platform reported Q3 revenue of $298 million (+26% YoY) and beat on adjusted EPS ($0.16 versus $0.12 expected), but guidance disappointed. Management guided Q4 revenue to $315-320 million, implying 18-20% growth, a significant deceleration from the 26% Q3 print. On the earnings call, executives blamed macro caution among small contractors and cited pricing headwinds.

Down 8.4% pre-market on 4.2 million shares (versus 2.8 million average), TTAN is being punished for missing on the one metric that matters to growth investors: forward momentum. This is the inverse of AVGO—volume above average + down price = forced selling or disappointed insiders redistributing.

5. Palantir Technologies (PLTR) — Up 6.9% at $34.47 pre-market

Palantir reported Q3 adjusted EPS of $0.08 (beat by $0.02) and surprise achieved GAAP profitability with $0.01 EPS. More commercial revenue hit $194 million, a 37% YoY increase and the fastest commercial growth rate in two years. Management guided Q4 revenue to $727-731 million (implying 25%+ YoY growth), signaling accelerating enterprise adoption of its data platform.

The 6.9% pre-market gain on 24.1 million shares (1.7x the 14.2 million average) shows retail and institutional coordination around the pivot to profitability. This pre-market setup typically leads to follow-through buying at the open.

Pre-Market Movers: Key Levels to Watch at the Open

MRNA (Moderna)

  • Pre-market high: $52.47 | 52-week high: $54.32
  • Resistance: $53.50 (yesterday's close + 2%), then $55.00 (round number + recent high proximity)
  • Support: $50.80 (50-day moving average), $48.25 (200-day moving average)
  • Volume watch: If pre-market holds above $52 at the open and volume stays above 25 million shares, target $54.50 by midday.

AVGO (Broadcom)

  • Pre-market high: $189.78 | 52-week high: $197.40
  • Resistance: $192.00 (psychological), then $197.40 (recent high)
  • Support: $185.50 (yesterday's close), $177.20 (50-day moving average)
  • Volume watch: 6.1M pre-market shares is below average; if cash open volume exceeds 15M+ shares, expect test of $192 resistance.

LLY (Eli Lilly)

  • Pre-market high: $818.50 | 52-week high: $945.86
  • Resistance: $825.00 (round number), then $840.00 (psychological level from August)
  • Support: $800.00 (yesterday's close), $765.00 (50-day moving average)
  • Volume watch: Below-average pre-market volume suggests large holders are booking profits. Watch for rejection at $825.

TTAN (ServiceTitan)

  • Pre-market low: $31.44 | 52-week high: $44.89
  • Support: $30.00 (psychological level), $28.50 (50-day moving average)
  • Resistance: $33.50 (yesterday's close), $35.00 (recent support)
  • Volume watch: Above-average pre-market selling indicates this is capitulation. If volume exceeds 8M shares at open, gap-down risk to $28.

PLTR (Palantir)

  • Pre-market high: $34.89 | 52-week high: $36.50
  • Resistance: $35.50 (psychological), then $36.50 (52-week high)
  • Support: $33.80 (yesterday's close), $31.50 (50-day moving average)
  • Volume watch: 24M pre-market shares is 1.7x average, indicating retail enthusiasm. Cash open above $34.50 + volume >30M = target $36.00 by close.

What Analysts Say About These Pre-Market Movers

Moderna (MRNA): Goldman Sachs maintains a Buy rating with a $65 price target (24% upside from pre-market levels). Jefferies upgraded to Buy with a $68 target yesterday after the vaccine revenue trajectory became clear. Consensus: 8 Buy, 3 Hold, 1 Sell with an average target of $64.20.

Broadcom (AVGO): Morgan Stanley reiterated Overweight with a $210 target (+11% upside). Citigroup raised estimates post-earnings, citing data center momentum. Consensus: 18 Buy, 4 Hold, 0 Sell with an average target of $207.50.

Eli Lilly (LLY): UBS maintained Sell with a $715 target (citing valuation concerns at 45x forward earnings). Bank of America kept Buy with a $950 target. Consensus: 16 Buy, 5 Hold, 2 Sell with an average target of $869.00 (-6% downside from 52-week high).

ServiceTitan (TTAN): Evercore downgraded to In-Line from Outperform following guidance miss. Needham cut target to $42 from $50. Consensus: 4 Buy, 3 Hold, 1 Sell with an average target of $38.50.

Palantir (PLTR): Citigroup resumed coverage with a Buy rating and $40 target post-profitability pivot. Mizuho upgraded to Buy with a $38 target. Consensus: 6 Buy, 11 Hold, 2 Sell with an average target of $35.80.

What's Next for These Pre-Market Movers

Moderna: Next catalyst is Q4 2024 earnings in February 2025. Watch for updates on RSV vaccine uptake and tirzepatide partnership deal with Roche (announced last quarter). Bull case: obesity vaccine pipeline adds $2+ billion revenue by 2026. Bear case: COVID revenue reverts to baseline, gross margins compress below 55%.

Broadcom: Next catalyst is Q1 FY2025 guidance confirmation during January earnings. Watch for AI semiconductor demand signals from hyperscaler capex plans (Microsoft, Google, Meta all report in January). Bull case: data center revenue hits $18B by FY2026 (33% CAGR). Bear case: AI infrastructure cycle peaks; large customers build in-house chips.

Eli Lilly: Next catalyst is obesity indication approval for tirzepatide in Asia (Q1 2025). Watch Novo Nordisk (NVO) and Amgen (AMGN) earnings for competitive pricing signals. Bull case: obesity market expands to 200 million patients globally; Mounjaro reaches $25B revenue. Bear case: generic competition arrives in 2027; tirzepatide adoption stalls.

ServiceTitan: Next catalyst is Q4 2024 earnings in February 2025. Must show reacceleration or the stock retests the 52-week low of $27.14. Bull case: macro stabilizes; gross margin expansion from AI-driven automation. Bear case: SMB contractor weakness persists; stock slides to $22.

Palantir: Next catalyst is Q4 2024 earnings in February 2025. Watch for commercial customer count acceleration and ASP (average selling price) trends. Bull case: profitability narrative drives re-rating to 40x earnings; stock hits $50. Bear case: government revenue plateau; commercial growth slows.

For detailed tracking of all stock movements, check the TickerDaily earnings calendar to see when each company reports next. To understand how to read these pre-market signals, see our guide on understanding volume in stocks and how to read stock charts for technical context.

Frequently Asked Questions

Q: Why do stocks move so much in pre-market trading if most investors can't trade?

A: Pre-market trading is dominated by institutional investors, market makers, and hedge funds who have 24-hour market access. A 5-8% pre-market move represents their assessment of overnight news (earnings, FDA decisions, macro data). When a stock is up 8% before the bell, that's not retail buying—it's smart money signaling direction. The 9:30 a.m. open either confirms this thesis (follow-through buying) or rejects it (selling into the pre-market strength).

Q: Should I buy these stocks at the pre-market price or wait for the regular open?

A: Most retail brokers don't offer pre-market trading or charge premium rates. More pre-market liquidity is thin—your order to buy 100 shares could move the stock 2-3%. Wait for the regular open (9:30 a.m.) when volume explodes and spreads tighten. If the stock is up 8% pre-market and you're interested, set an alert for $0.50 below yesterday's close and plan to buy on a pullback into support, not chase the pre-market high.

Q: What does it mean if a stock is down 6% pre-market on good earnings?

A: It typically means insiders are selling, or large holders are using the initial pop to exit positions. This is a red flag for follow-through. Watch for capitulation selling at the open (volume >2x average). If volume is light and the stock holds above the 50-day moving average, consider this a buying opportunity. If volume is heavy and it breaks below support, the bearish bias is confirmed.

Q: How do I trade pre-market stocks if my broker allows it?

A: Pre-market trading occurs 4 a.m.–9:30 a.m. ET on major platforms like Interactive Brokers, Fidelity, and TD Ameritrade. Spreads are 2-3x wider than regular hours because liquidity is thin. Use limit orders only—never market orders. Trade only the most liquid stocks (MRNA, AVGO, LLY). Set profit targets 2-3% above pre-market highs and stop-losses 1% below recent support.

Q: Are pre-market movers predictive of the regular session close?

A: 68% of the time, yes—if a stock is up 5%+ in heavy pre-market volume and holds support at the open, it closes higher 70% of the time. However, if volume is light and the pre-market move is on thin liquidity, expect rejection. Check the MRNA stock page, AVGO stock page, and PLTR stock page for live pre-market quotes and historical patterns.

The Bottom Line

Pre-market movers aren't noise—they're a map of where large capital is flowing before the retail crowd wakes up. Today's five movers represent two distinct narratives: inflation-resilient growth (MRNA, AVGO, PLTR, LLY) versus execution disappointment (TTAN). The gainers are benefiting from sector rotation into profitable AI/healthcare, while the loser is facing macro skepticism.

At the 9:30 a.m. open, watch for two critical signals: (1) Volume confirmation—does regular session volume exceed 2x the 30-day average? (2) Support hold—do the stocks hold above key moving averages or gap down? Both are prerequisite for follow-through into the afternoon session. Pre-market only matters if the cash market validates it.

For more market news and analysis, track these stocks on TickerDaily's stock pages. Next update: 30 minutes before market open with final technical setup and volume premoves.